| A | B | C | D | E | F | G | H | I | J | K | L | M | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | |||||||||||||
| 2 | Name | MOA | Economics | Phase | Indication | Price | 35.67 | ||||||
| 3 | aficamten | Shares | 607.2236809999999 | Q422 | |||||||||
| 4 | ampreloxetine | MC | 21659.66870127 | ||||||||||
| 5 | BCX10013 | Cash | 2472 | Q422 | |||||||||
| 6 | MK-8189 | PDE10A inhibitor | MRK | Schizophrenia | Debt | 7116 | Q422 | ||||||
| 7 | olpsairan | LP(a) siRNA | AMGN | EV | 26303.66870127 | ||||||||
| 8 | omecamtiv mecarbil | CYTK | |||||||||||
| 9 | pelabresib | BET inhibitor | MOR | Myelofibrosis | |||||||||
| 10 | pelacarsen | NVS | |||||||||||
| 11 | seltorexant | Orexin 2 antagonist | JNJ | Insomnia | |||||||||
| 12 | trontinemab | transferrin-gantenerumab | Roche | Alzheimer's | Company: executive officers | ||||||||
| 13 | tulmimetostat | EZH2 inhibitor | MOR | Manager: 75 employees | |||||||||
| 14 | zavegepant | CGRP | PFE | Migraine | |||||||||
| 15 | |||||||||||||
| 16 | |||||||||||||
| 17 | Tazverik |